By Fineline Cube 
South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380) has entered into a licensing agreement with GlaxoSmithKline (GSK, NYSE: GSK). The collaboration grants GSK access to ABL Bio’s Grabody-B blood-brain barrier (BBB) shuttle platform to develop novel medicines for neurodegenerative diseases. The deal encompasses multiple programs across therapeutic modalities, including antibodies, polynucleotides, and oligonucleotides such as siRNA and ASOs.
Agreement Details
Under the terms of the agreement, GSK will pay ABL Bio up to GBP 77.1 million (USD 99.6 million) in upfront and near-term payments, including an immediate upfront payment of GBP 38.5 million (USD 49.7 million). Additional payments could reach up to GBP 2.075 billion (USD 2.68 billion) for research, development, regulatory, and commercialization milestones, alongside tiered royalties on net sales.
Technology Transfer and Development
GSK will assume responsibility for preclinical and clinical development, manufacturing, and commercialization of products derived from the Grabody-B platform. This technology enables the efficient delivery of therapeutic agents across the blood-brain barrier, a critical advancement for treating neurodegenerative conditions.-Fineline Info & Tech